Stay updated on the latest from the European tech scene, exclusive insights from our founder Boris, and quirky AI art, delivered to your inbox for free every week. Subscribe now!
“Inne focuses on the daily status of your hormones, providing more accurate and precise information compared to traditional period and temperature tracking methods,” said Eirini Rapti, the founder of Inne. This innovative approach addresses the complexities of the human body, offering a deeper understanding of hormonal patterns.
Users analyze photos taken by the Minilab, employing biochemistry and image processing techniques to monitor hormone levels. This data is then transferred to a mobile app, allowing users to track their hormone fluctuations throughout their menstrual cycle, gaining insight into fertility, contraception options, and overall hormonal health.
Eirini Rapti highlighted that Inne’s technology aims to help women avoid the side effects associated with hormone-based contraceptives and offer a non-invasive birth control option.
The Minilab is available through a subscription plan, starting at €24 per month for a two-year commitment with upfront payment. Germany’s largest health insurer has recently included coverage for this device, and Inne aims to expand this coverage to more providers in the future.
Inne is part of a wave of technology-driven contraceptive solutions that have emerged recently, meeting the demand for hormone-free alternatives to traditional birth control methods like the pill or IUD.
With regulatory approval in hand, Inne’s birth control solution is now available in Germany and Austria, with plans for further expansion to the UK later this year.
Inne’s Minilab was initially introduced as a fertility aid for women looking to conceive. However, it recently received approval as a contraceptive device from the British Standards Institution, a key regulatory body for medical devices in Europe.
The innovative saliva-based fertility tracker developed by Inne, known as the “Minilab,” has been approved as a contraceptive method in Europe. This at-home testing device tracks daily progesterone levels, which play a crucial role in the menstrual cycle.
This device presents itself as a promising non-invasive option for birth control, diverging from traditional hormonal methods like the pill. Early tests have shown positive results, indicating its effectiveness.
